Theravance Biopharma (TBPH) shares ended the last trading session 8.3% higher at $10.47. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.9% loss over the past four weeks.

The company has developed Yupelri, a nebulized treatment for chronic obstructive pulmonary disease, in collaboration with Viatris. Theravance is also developing ampreloxetine in late-stage studies for treating neurogenic orthostatic hypotension in patients with multiple system atrophy. The growing optimism related to encouraging pipeline progress, along with the uptake of Yupelri, might have driven the recent share price rally.

This biopharmaceutical company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of -266.7%. Revenues are expected to be $35.19 million, up 100.3% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Theravance Bio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TBPH going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Theravance Bio is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, electroCore, Inc. (ECOR), finished the last trading session 7.4% higher at $17.01. ECOR has returned -5.5% over the past month.

For electroCore , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.34. This represents a change of +44.3% from what the company reported a year ago. electroCore currently has a Zacks Rank of #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report

electroCore, Inc. (ECOR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research